 |
Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant pleural mesothelioma |
| USA Market Approval | USA |
| USA Designation Date | 2002-02-11 00:00:00 |
| Sponsor | National Institutes of Health;Cancer Therapy Evaluation Program, 6130 Executive Blvd, Suite 7111;Rockville, Maryland, 20852 |
